BR112015020604A2 - vírus da leucemia bovina (blv) atenuado recombinante, ácido nucleico, vetor, plasmídeo, célula hospedeira, composição farmacêutica, vacina, animal não humano, método de obtenção de material de animal não humano e material derivado de animal não humano - Google Patents
vírus da leucemia bovina (blv) atenuado recombinante, ácido nucleico, vetor, plasmídeo, célula hospedeira, composição farmacêutica, vacina, animal não humano, método de obtenção de material de animal não humano e material derivado de animal não humanoInfo
- Publication number
- BR112015020604A2 BR112015020604A2 BR112015020604A BR112015020604A BR112015020604A2 BR 112015020604 A2 BR112015020604 A2 BR 112015020604A2 BR 112015020604 A BR112015020604 A BR 112015020604A BR 112015020604 A BR112015020604 A BR 112015020604A BR 112015020604 A2 BR112015020604 A2 BR 112015020604A2
- Authority
- BR
- Brazil
- Prior art keywords
- human animal
- blv
- recombinant
- bovine leukemia
- vaccine
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title abstract 6
- 102000039446 nucleic acids Human genes 0.000 title abstract 6
- 108020004707 nucleic acids Proteins 0.000 title abstract 6
- 239000013598 vector Substances 0.000 title abstract 5
- 241000714266 Bovine leukemia virus Species 0.000 title abstract 4
- 230000002238 attenuated effect Effects 0.000 title abstract 4
- 239000000463 material Substances 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- 239000013612 plasmid Substances 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14041—Use of virus, viral particle or viral elements as a vector
- C12N2740/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14061—Methods of inactivation or attenuation
- C12N2740/14062—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
- C12N2740/14071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
resumo vírus da leucemia bovina (blv) atenuado recombinante, ácido nucleico, vetor, plasmídeo, célula hospedeira, composição farmacêutica, vacina, animal não humano, método de obtenção de material de animal não humano e material derivado de animal não humano a presente invenção refere-se a vírus da leucemia bovina recombinantes que possuem fenótipo atenuado e compreendem uma combinação de pelo menos duas mutações específicas. a presente invenção também fornece ácidos nucleicos recombinantes que codificam esses vírus, vetores que compreendem esses ácidos nucleicos e células hospedeiras que compreendem esses ácidos nucleicos ou vetores. os vírus blv atenuados recombinantes, ácidos nucleicos recombinantes, vetores e células hospedeiras permitem a preparação de vacinas aprimoradas, particularmente vacinas apropriadas para o tratamento profilático de doenças associadas a blv em pacientes. a presente invenção fornece ainda métodos de tratamento de doenças associadas a blv em pacientes e composições farmacêuticas apropriadas para uso nesses métodos.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361769971P | 2013-02-27 | 2013-02-27 | |
| EP13156921 | 2013-02-27 | ||
| US61/769,971 | 2013-02-27 | ||
| EP13156921.2 | 2013-02-27 | ||
| PCT/EP2014/053855 WO2014131844A1 (en) | 2013-02-27 | 2014-02-27 | Vaccine against bovine leukemia virus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112015020604A2 true BR112015020604A2 (pt) | 2017-10-10 |
| BR112015020604B1 BR112015020604B1 (pt) | 2023-11-21 |
Family
ID=47749713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112015020604-2A BR112015020604B1 (pt) | 2013-02-27 | 2014-02-27 | Vírus da leucemia bovina, vetor, célula hospedeira, composição farmacêutica e uso de um vírus da leucemia bovina |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US10029006B2 (pt) |
| EP (1) | EP2961425B1 (pt) |
| AR (1) | AR094912A1 (pt) |
| BR (1) | BR112015020604B1 (pt) |
| CA (1) | CA2901508A1 (pt) |
| MX (1) | MX358118B (pt) |
| WO (1) | WO2014131844A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3113817A1 (en) * | 2018-10-09 | 2020-04-16 | The University Of North Carolina At Chapel Hill | Regulated gene editing system |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2396978C1 (ru) | 2009-03-05 | 2010-08-20 | Федеральное государственное образовательное учреждение высшего профессионального образования Курская государственная сельскохозяйственная академия имени профессора И.И. Иванова | Способ профилактики развития лейкоза крупного рогатого скота |
-
2014
- 2014-02-27 CA CA2901508A patent/CA2901508A1/en not_active Abandoned
- 2014-02-27 AR ARP140100623A patent/AR094912A1/es active IP Right Grant
- 2014-02-27 MX MX2015011064A patent/MX358118B/es active IP Right Grant
- 2014-02-27 WO PCT/EP2014/053855 patent/WO2014131844A1/en active Application Filing
- 2014-02-27 BR BR112015020604-2A patent/BR112015020604B1/pt active IP Right Grant
- 2014-02-27 EP EP14711458.1A patent/EP2961425B1/en not_active Not-in-force
-
2015
- 2015-08-21 US US14/832,863 patent/US10029006B2/en active Active
-
2018
- 2018-06-12 US US16/006,472 patent/US11154611B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2961425A1 (en) | 2016-01-06 |
| CA2901508A1 (en) | 2014-09-04 |
| US11154611B2 (en) | 2021-10-26 |
| US20160045593A1 (en) | 2016-02-18 |
| US10029006B2 (en) | 2018-07-24 |
| AR094912A1 (es) | 2015-09-09 |
| MX358118B (es) | 2018-08-06 |
| BR112015020604B1 (pt) | 2023-11-21 |
| EP2961425B1 (en) | 2018-05-30 |
| WO2014131844A1 (en) | 2014-09-04 |
| MX2015011064A (es) | 2016-03-01 |
| US20190000963A1 (en) | 2019-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019001887A2 (pt) | composições e métodos para o tratamento de doença associada a cep290 | |
| SA517390590B1 (ar) | Ix عامل معدل، وتركيبات وطرق واستخدامات لنقل الجين إلى الخلايا، والأعضاء والأنسجة | |
| BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
| PH12017501287A1 (en) | A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist | |
| BR112018011975A2 (pt) | composições úteis no tratamento de atrofia muscular espinhal | |
| SG10201901482XA (en) | Oncolytic adenovirus encoding a b7 protein | |
| BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
| BR112016016658A2 (pt) | proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão | |
| WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
| BR112018017307A2 (pt) | molécula de ácido nucleico isolada, composição, e, métodos para indução de uma resposta imune contra um zika vírus, para tratamento de um indivíduo e para prevenção de uma infecção por zika vírus | |
| BR112018008766A2 (pt) | variantes, composições e métodos e utilizações do fator viii reduzido cpg para o tratamento de transtornos hemostásicos | |
| BR112014008694A2 (pt) | moléculas de ácido nucleico policistrônico recombinante | |
| HK1225631A1 (zh) | 免疫原性中東呼吸綜合征冠狀病毒(mers-cov)組合物和方法 | |
| MX389093B (es) | Composiciones y metodos para la glicosilacion de proteinas. | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
| IN2015DN02546A (pt) | ||
| BR112018006006A2 (pt) | receptores de antígeno, cadeias peptídicas, células recombinantes, métodos para produzir uma célula que expressa um receptor de antígeno e para o tratamento de uma doença, ácidos nucleicos e composição farmacêutica | |
| MY199929A (en) | Canine adenovirus vectors | |
| BR112012028893A2 (pt) | composições imunoestimuladoras e de vacina | |
| EA201691981A1 (ru) | Улучшенные транспортные молекулы модулярного антигена и их применение | |
| PH12017501100A1 (en) | Recombinant swinepox virus and vaccines | |
| EA201890274A1 (ru) | Векторная система из аденовируса 9 птиц (fadv-9) и связанные способы | |
| ZA202003070B (en) | Lassa vaccine | |
| MX2019007924A (es) | Vacunas contra la influenza. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] |
Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI. |
|
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B09W | Correction of the decision to grant [chapter 9.1.4 patent gazette] |
Free format text: AO PRESENTE PEDIDO FOI EXARADO O PARECER DE DEFERIMENTO, NOTIFICADO NA RPI NO 2752 DE 03/10/2023. VIA MENSAGEM DO FALE CONOSCO NO 1169133, FOI INFORMADO QUE HA INCORRECAO NO TITULO DO PARECER DE DEFERIMENTO. ASSIM, RETIFICO A REFERIDA PUBLICACAO COM O TITULO CORRETO:?VIRUS DA LEUCEMIA BOVINA, VETOR, CELULA HOSPEDEIRA, COMPOSICAO FARMACEUTICA E USO DE UM VIRUS DA LEUCEMIA BOVINA? |
|
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/02/2014, OBSERVADAS AS CONDICOES LEGAIS |